Adaptive biotechnologies stock.

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to …

Adaptive biotechnologies stock. Things To Know About Adaptive biotechnologies stock.

Watch Adaptive Biotechnologies stock price move in real-time ahead here. On February 14, Adaptive Biotechnologies will release earnings for the most recent quarter.Discover historical prices for ADPT stock on Yahoo Finance. View daily, weekly or monthly format back to when Adaptive Biotechnologies Corporation stock was issued. Complete Adaptive Biotechnologies Corp. stock information by Barron's. View real-time ADPT stock price and news, along with industry-best analysis.Nov 30, 2023 · Adaptive Biotechnologies Corp ADPT Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation... Adaptive Biotechnologies (ADPT) Stock Forecast & Price Target

View today's Adaptive Biotechnologies Corp stock price and latest ADPT news and analysis. Create real-time notifications to follow any changes in the live stock price.Find the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing.The whole human proteome may be free to browse thanks to DeepMind, but at the bleeding edge of biotech new proteins are made and tested every day, a complex and time-consuming process. Glyphic Biotechnologies accelerates the critical but sl...

Adaptive Biotechnologies Corp ADPT Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation...Adaptive Biotechnologies (NASDAQ: ADPT) $4.31 (6.9%) $0.28 Price as of November 17, 2023, 4:00 p.m. ET Overview Return vs. S&P News & Analysis Financial Health …

Adaptive Biotechnologies. SEATTLE, April 06, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company ...Feb. 14, 2024 (est.) Last Earnings Release. Nov. 09, 2023. Next Ex-Dividend Date. N/A. Last Ex-Dividend Date. N/A. In depth view into ADPT (Adaptive Biotechnologies) stock including the latest price, news, dividend history, earnings information and financials.Adaptive Biotechnologies Corp stock performance at a glance. Check Adaptive Biotechnologies Corp’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. ADPT Stock Performance. USD USD; Previous close: 4.38: 4.38: Day range: 4.21 - 4.774.21 - 4.77Year range: 2 - 10Feb. 14, 2024 (est.) Last Earnings Release. Nov. 09, 2023. Next Ex-Dividend Date. N/A. Last Ex-Dividend Date. N/A. In depth view into ADPT (Adaptive Biotechnologies) stock including the latest price, news, dividend history, earnings information and financials.

Nov 30, 2023 · Get Adaptive Biotechnologies Corp (ADPT.N) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments ... 12 Feb 2024 / 10:59 AM UTC Q4 2023 ...

The stock price for . Adaptive Biotechnologies (NASDAQ: ADPT) is $4.4 last updated Today at November 30, 2023 at 9:44 PM UTC. Q Does Adaptive Biotechnologies (ADPT) pay a dividend?

You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Get the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. See the performance outlook, earnings date, dividend yield, research reports and more for ADPT on NasdaqGS.Oct 17, 2023 · The latest Adaptive Biotechnologies Corporation Registered Shs stock prices, stock quotes, news, and ADPT history to help you invest and trade smarter. Interested individuals can access further details through the hyperlink provided by Adaptive Biotechnologies. Overall insider trading activity for Adaptive Biotechnologies has been noteworthy, with insiders recently selling 242,961 shares of the company’s stock. These transactions have amounted to a total value of $1,967,763.Jun 30, 2022 · SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended ...

SEATTLE, July 15, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $40.00 ...Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.44 per share a year ago.Adaptive Biotechnologies Corp stock performance at a glance. Check Adaptive Biotechnologies Corp’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. ADPT Stock Performance. USD USD; Previous close: 4.38: 4.38: Day range: 4.21 - 4.774.21 - 4.77Year range:Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …Shares of Adaptive Biotechnologies ... The clinical-stage biotech company's stock closed last week at $7.31, then rose to as high as $9.08 on Wednesday. The stock is up a little more than 10% so ...

SEATTLE, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the commencement of a proposed underwritten public offering …

Description. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to …Description. Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to …Get the latest Adaptive Biotechnologies Corporation ADPT detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Adaptive is powering immune medicine in the most unique way—and we’re looking for individuals who want to build a story, not just a resume. If you want to go beyond the impossible—Adaptive is where you’ll discover your story. You’ll tackle big, interesting, highly impactful problems that lead to a future you can help write.Interested individuals can access further details through the hyperlink provided by Adaptive Biotechnologies. Overall insider trading activity for Adaptive Biotechnologies has been noteworthy, with insiders recently selling 242,961 shares of the company’s stock. These transactions have amounted to a total value of $1,967,763.On November 9, Adaptive Biotechnologies will report earnings from Q3. Wall Street analysts predict losses per share of $0.339. Track Adaptive Biotechnologies stock price in real-time ahead here ...The average twelve-month price prediction for Adaptive Biotechnologies is $9.50 with a high price target of $15.00 and a low price target of $6.00. Learn more on ADPT's analyst rating history. Do Wall Street analysts like Adaptive Biotechnologies more than its competitors? Analysts like Adaptive Biotechnologies less than other Medical companies.Apr 25, 2023 · Adaptive Biotechnologies Corp is down 9.82% from its previous closing price of $8.25. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.20 and $8.61. Currently, there are 143.06 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive Biotechnologies Corp’s P ... Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. 11-02-2023 at 4:07 PM EDT. Adaptive Announces Launch of Epic Integration for clonoSEQ®. 09-13-2023 at 7:31 AM EDT. Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference. 08-30 …

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 7.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Nov 29, 2023 · Get a real-time Adaptive Biotechnologies Corporation (ADPT) stock price quote with breaking news, financials, statistics, charts and more. ... The 12-month stock ...

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to …Second Quarter 2023 Financial Results. Revenue was $48.9 million for the quarter ended June 30, 2023, representing a 12% increase from the second quarter in the prior year. Immune Medicine revenue was $23.0 million for the quarter, representing a 3% increase from the second quarter in the prior year.Scroll through Adaptive Biotechnologies’ timeline and learn how we have arrived at the precipice of transforming medicine. Our milestones show how we are harnessing the natural capabilities of the immune system to develop clinical …Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic …Adaptive Biotechnologies Corporation published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 10 January 2022 20:27:03 UTC .The average twelve-month price prediction for Adaptive Biotechnologies is $9.50 with a high price target of $15.00 and a low price target of $6.00. Learn more on ADPT's analyst rating history. Do Wall Street analysts like Adaptive Biotechnologies more than its competitors? Analysts like Adaptive Biotechnologies less than other Medical companies.Adaptive Biotechnologies ( ADPT) reported Q3 2023 earnings per share (EPS) of -$0.35, missing estimates of -$0.34 by 2.64%. In the same quarter last year, Adaptive Biotechnologies 's earnings per share (EPS) was -$0.32. Adaptive Biotechnologies is expected to release next earnings on 02/19/2024, with an earnings per share (EPS) …So consider, for a moment, the misfortune of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) investors who have held the stock for three years as it declined a whopping 82%.

Taking the right travel adapter with you will ensure you're never without — but with so many types, it can be tricky to know what you need. We may be compensated when you click on product links, such as credit cards, from one or more of our...SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical ...The whole human proteome may be free to browse thanks to DeepMind, but at the bleeding edge of biotech new proteins are made and tested every day, a complex and time-consuming process. Glyphic Biotechnologies accelerates the critical but sl...Instagram:https://instagram. uhual stocksing otcdoes medicaid covers bracescrypto.com news What percentage of Adaptive Biotechnologies stock is owned by insiders? 5.20% of Adaptive Biotechnologies stock is owned by insiders. Learn more on ADPT's insider holdings.Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s traded shares stood at 0.53 million during the last session, with the company’s beta value hitting 1.21. At the close of trading, the stock’s price was $4.21, to imply a decrease of -0.94% or -$0.04 in intraday trading. The ADPT share’s 52-week ... us corp bankbest mortgage lenders for first time buyers The stock price for . Adaptive Biotechnologies (NASDAQ: ADPT) is $4.4 last updated Today at November 30, 2023 at 9:44 PM UTC. Q Does Adaptive Biotechnologies (ADPT) pay a dividend?SEATTLE, June 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, will be included in several oral and poster presentations investigating the clinical ... inivo stock Wall Street Stock Market & Finance report, prediction for the future: You'll find the Adaptive Biotechnologies share forecasts, stock quote and buy / sell signals below. According to present data Adaptive Biotechnologies's ADPT shares and potentially its market environment have been in bearish cycle last 12 months (if exists).SEATTLE, July 15, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of an underwritten public offering of 8,000,000 shares of its common stock at a public offering price of $40.00 ...